


ABSTRACT

The present application describes novel hydantoin derivatives of formula (I):



- 5 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R¹¹ are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF- α converting enzyme (TACE), aggrecanase, or a combination thereof.

10